Blowing the whistle on drug firms
Last December, a specialty pharmacy in Florida enjoyed its best month ever — posting a hefty $168.7 million in revenues.
But it wasn't filling prescriptions that made Ven-A-Care of the Florida Keys Inc. such a success.
Tiny Ven-A-Care has developed a lucrative niche market: blowing the whistle on drug companies that overcharge Medicare and Medicaid — and collecting tens of millions of dollars in reward money.
Unlike most whistle-blowers who help the government with one case after they encounter wrongdoing, Ven-A-Care has filed suits alleging fraudulent conduct against dozens of drug companies supplying pharmacies and healthcare providers. Complete Article
Tuesday, January 25, 2011
Big PhRMA Behind Millions in Medicare Fraud
This issue is close to me because I am sure Medicare fraud is involved in my late mother's care. A person with a closed head injury and expressive aphasia needs a neurologist to be their primary care provider, not a questionable shrink who loaded her up on expensive psych drugs. Hyatt surely made out like a bandit on this one too, yet my greedy, controlling brother in Vermont, her POA, did NOTHING to make a change. My mother was warehoused in Florida at a so-called '5 star' facility.
Labels:
Hyatt,
Medicare fraud
Subscribe to:
Post Comments (Atom)
4 comments:
Wow i love you blog its awesome nice colors you must have did hard work on your blog. Keep up the good work. Thanks
Wow i love you blog its awesome nice colors you must have did hard work on your blog. Keep up the good work. Thanks
Thanks for taking this opportunity to talk about this, I feel fervently about it and I like learning about this subject. Please, as you gain data, please update this blog with more information. I have found it very useful. I want to share some of my knowledge regarding with weight loss etc. Thanks ",)
Found this in an old file, from the ‘Auckland Star’ under ‘World News.’
“We have to remember that the main aim of pharmaceutical companies is not to make drugs for the good of mankind, but to make profits for their shareholders.”
Brewster Ashley,
Director of the Therapeutic Goods Administration Drug Evaluation Branch, Australia.
Post a Comment